Taking T-Cell Oncotherapy Off-the-Shelf

Feiyan Mo, Maksim Mamonkin, Malcolm K. Brenner, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Banked allogeneic or ‘off-the-shelf’ (OTS) T cells from healthy human donors are being developed to address the limitations of autologous cell therapies. Potential challenges of OTS T cell therapies are associated with their allogeneic origin and the possibility of graft-versus-host disease (GvHD) and host-versus-graft immune reactions. While the risk of GvHD from OTS T cells has been proved to be manageable in clinical studies, approaches to prevent immune rejection of OTS cells are at an earlier stage of development. We provide an overview of strategies to generate OTS cell therapies and mitigate alloreactivity-associated adverse events, with a focus on recent advances for preventing immune rejection.

Original languageEnglish (US)
Pages (from-to)261-272
Number of pages12
JournalTrends in Immunology
Issue number3
StatePublished - Mar 2021


  • Allogeneic banked cells
  • Immune effectors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Taking T-Cell Oncotherapy Off-the-Shelf'. Together they form a unique fingerprint.

Cite this